LAVA Begin Period Cash Flow from 2010 to 2024

LVTX Stock  USD 1.60  0.05  3.23%   
LAVA Therapeutics Begin Period Cash Flow yearly trend continues to be fairly stable with very little volatility. Begin Period Cash Flow will likely drop to about 51.7 M in 2024. Begin Period Cash Flow is the amount of cash LAVA Therapeutics NV has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2018-12-31
Previous Quarter
44.2 M
Current Value
43.2 M
Quarterly Volatility
48.1 M
 
Covid
Check LAVA Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LAVA Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 158.4 K, Net Interest Income of 3.1 M or Depreciation And Amortization of 1.3 M, as well as many indicators such as Price To Sales Ratio of 5.93, Dividend Yield of 0.0 or PTB Ratio of 0.78. LAVA financial statements analysis is a perfect complement when working with LAVA Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LAVA Therapeutics Correlation against competitors.

Latest LAVA Therapeutics' Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of LAVA Therapeutics NV over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. LAVA Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LAVA Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

LAVA Begin Period Cash Flow Regression Statistics

Arithmetic Mean28,715,170
Geometric Mean21,422,700
Coefficient Of Variation100.28
Mean Deviation20,901,095
Median16,002,000
Standard Deviation28,795,096
Sample Variance829.2T
Range90.5M
R-Value0.62
Mean Square Error548.6T
R-Squared0.39
Significance0.01
Slope3,998,391
Total Sum of Squares11608.2T

LAVA Begin Period Cash Flow History

202451.7 M
2023100.3 M
202290.9 M
202117.9 M
20209.9 M

About LAVA Therapeutics Financial Statements

LAVA Therapeutics investors use historical fundamental indicators, such as LAVA Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LAVA Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Begin Period Cash Flow100.3 M51.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.